<DOC>
	<DOCNO>NCT00392990</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin hydrochloride liposome , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving rituximab together combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give doxorubicin hydrochloride liposome rituximab together combination chemotherapy work treat patient newly diagnose Burkitt 's lymphoma Burkitt-like lymphoma .</brief_summary>
	<brief_title>Doxorubicin Hydrochloride Liposome Rituximab With Combination Chemotherapy Treating Patients With Newly Diagnosed Burkitt 's Lymphoma Burkitt-Like Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate ( complete remission , complete remission undetermined , partial remission ) HIV-negative HIV-positive patient newly diagnose Burkitt 's Burkitt-like lymphoma treat doxorubicin hydrochloride liposome rituximab part Magrath regimen . Secondary - Determine complete remission rate patient treat regimen . - Determine progression-free overall survival 2 year patient treat regimen . - Determine safety add rituximab standard Magrath regimen patient . - Determine safety use doxorubicin hydrochloride liposome place doxorubicin hydrochloride patient . - Determine correlative level rituximab doxorubicin hydrochloride liposome cerebrospinal fluid peripheral blood . OUTLINE : This multicenter study . Patients stratify accord risk category ( low risk v high risk ) . Patients assign 1 2 treatment regimen accord stratum . - Regimen A ( low-risk disease CNS involvement ) : Patients receive R-CODOX-M chemotherapy comprise rituximab IV 2-4 hour day 0 8 ; doxorubicin hydrochloride liposome IV 30 minute day 1 ; vincristine IV day 1 8 ; cyclophosphamide IV 1 hour day 1-5 ; high-dose methotrexate ( MTX ) IV 24 hour day 10 . Patients also receive leucovorin calcium IV begin 36 hour start MTX infusion continue every 6 hour blood level MTX safe . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 4-8 course 1 3 day 6 7 course 2 . Beginning day 12 , daily G-CSF dosing resume blood count recover . Patients receive CNS prophylaxis comprise cytarabine intrathecally ( IT ) day 1 MTX IT day 3 . Treatment repeat every 28 day 3 course absence disease progression unacceptable toxicity . - Regimen B ( high-risk disease without CNS involvement ) : Patients receive R-CODOX-M chemotherapy leucovorin calcium G-CSF support regimen A course 1 3 R-IVAC chemotherapy leucovorin calcium G-CSF support ( ) course 2 4 . R-IVAC chemotherapy comprise high-dose ifosfamide IV 3 hour etoposide IV 1 hour day 1-5 ; cytarabine IV 3 hour twice daily day 2 3 ; rituximab IV 2-4 hour day 0 day 6 7 . Patients also receive leucovorin calcium orally every 6 hour day 6 G-CSF SC daily begin day 6 7 continue blood count recover . Patients without CNS involvement receive CNS prophylaxis comprise cytarabine IT day 1 3 MTX IT day 15 course 1 3 MTX IT alone day 5 course 2 4 . Patients proven CNS involvement diagnosis receive cytarabine IT day 1 , 3 , 5 course 1 , day 7 9 course 2 , day 1 3 course 3 . These patient also receive MTX IT day 15 17 course 1 , day 5 course 2 4 , day 15 course 3 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . The first 10 patient enrol study undergo cerebrospinal fluid blood collection course 1 3 correlative biological marker pharmacological study . After completion study treatment , patient follow 30 day periodically 3 year . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Burkitt 's Burkittlike nonHodgkin 's lymphoma meeting 1 follow risk criterion : Lowrisk disease meeting follow criterion : Normal lactate dehydrogenase level ECOG performance status 01 Ann Arbor stage I II No tumor mass 10 cm great diameter Highrisk disease , define disease meeting lowrisk criterion Newly diagnose disease PATIENT CHARACTERISTICS : ECOG performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Hemoglobin ≥ 8.0 g/dL Absolute neutrophil count ≥ 500/mm³ Platelet count ≥ 100,000/mm³ ( 50,000/mm³ bone marrow involvement document ) AST ALT ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN Bilirubin ≤ 1.5 time ULN ( 3 time ULN liver metastasis present ) Creatinine clearance &gt; 50 mL/min Creatinine ≤ 2.0 mg/dL LVEF ≥ 45 % MUGA scan echocardiogram No New York Heart Association class IIIV heart failure No clinically significant pericardial disease No myocardial infarction within past 6 month No uncontrolled angina No severe uncontrolled ventricular arrhythmia No ECG evidence acute ischemia active conduction system abnormality Investigator must document baseline ECG abnormality medically relevant No malignancy within past year except basal cell carcinoma skin situ carcinoma cervix No serious medical psychiatric illness would preclude study compliance PRIOR CONCURRENT THERAPY : Prior treatment 1 course combination rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine , and/or prednisone* ( CHOP ) like therapy allow , provide follow dos exceed : Rituximab 750 mg/m² Cyclophosphamide 1,000 mg/m² Doxorubicin hydrochloride 50 mg/m² Vincristine 2 mg/m² No investigational drug within past 14 day No concurrent systemic , cytotoxic , investigational , chemotherapy agent NOTE : *No maximum dose restriction steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
</DOC>